Skip to main content
Biomark Diagnostics Inc. logo

Biomark Diagnostics Inc. — Investor Relations & Filings

Ticker · BUX LEI · 529900UHZ378KKXOLY69 CSE Professional, scientific and technical activities
Open in API
Filings indexed 142 across all filing types
Latest filing 2026-04-14 Regulatory Filings
Country CA Canada
Listing CSE BUX

About Biomark Diagnostics Inc.

https://www.biomarkdiagnostics.com/

Biomark Diagnostics Inc. is an oncology-focused company developing advanced liquid biopsy diagnostic technologies for the early detection, monitoring, and screening of cancer. The core technology platform utilizes metabolomics, the study of biomarkers and metabolites, integrated with Artificial Intelligence and Machine Learning algorithms. This approach aims to provide rapid, accurate results for hard-to-detect cancers, thereby improving patient outcomes. The company's pipeline includes the Liquid Biopsy SSAT1 Assay and a Metabolic Panel.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a corporate press release announcing BioMark Diagnostics’ selection to present at a research forum and describing its technology and forward-looking statements. It is not an earnings release, financial report, board change, capital update, or any of the specific filings listed. It is a general corporate announcement without regulatory filing specifics, so it falls into the fallback category Regulatory Filings (RNS).
2026-04-14 English
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a press release announcing that BioMark Diagnostics will present its liquid biopsy platform at a research forum. It does not contain financial results (ER/IR/10-K/IR), capital/financing details (CAP), changes in management (MANG), voting or AGM materials (AGM-R/DVA), dividends (DIV), M&A (TAR), share transactions (DIRS/POS/SHA), ESG metrics (SR), or other specific report types. It also is not an investor presentation deck (IP) but rather a general corporate news release. It does not correspond to any dedicated category, so it falls under the fallback “Regulatory Filings” category (RNS).
2026-04-14 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release issued by BioMark Diagnostics Inc. announcing the initiation of an ISO 15189 accreditation program. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding operational strategy and regulatory milestones, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate news.
2025-12-23 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109FV2', which is a Venture Issuer Basic Certificate for interim filings. This is a regulatory certification document required by securities legislation to accompany interim financial reports. Since it is a specific regulatory filing that does not fit into the primary financial report categories (like 10-K or IR) and is not an announcement of a report, it falls under the 'Regulatory Filings' category.
2025-11-29 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109FV2 Certification of Interim Filings', which is a regulatory requirement for venture issuers to certify the accuracy of their interim financial reports and MD&A. Since this is a standalone regulatory certification document rather than the interim report itself or a general announcement, it falls under the category of Regulatory Filings (RNS) as it is a specific compliance filing that does not fit into the other specialized categories like IR or MDA.
2025-11-29 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is explicitly titled 'Management’s Discussion & Analysis' and 'Quarterly Report' for the period ended September 30, 2025. It follows the standard format for MD&A filings (Form 51-102F1), providing a detailed narrative explanation of the company's financial results, business trends, and operational outlook. It is not an earnings release (which is a summary) nor a report publication announcement (as it contains the full content of the report). Therefore, it is classified as a Management Report (MDA).
2025-11-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.